Adare Pharmaceuticals
Princeton Pike Corporate Center
1200 Lenox Drive, Suite 100
Lawrenceville
New Jersey
08648
United States
Tel: 1-609-450-1312
Fax: 1-609-896-1404
Website: http://www.adarepharma.com/
Email: BusDev@adarepharma.com
About Adare Pharmaceuticals
Adare Pharmaceuticals transforms medicines, creating new possibilities for improved patient health. We have expertise in overcoming complex formulation challenges and adding valuable IP to new and existing products—resulting in medicines that deliver greater value to all stakeholders, while meeting the needs of patients. We have the ability to transform drug formulations using our proprietary technologies, developing novel Rx and OTC products. Adare is uniquely suited to unlock the potential of more medicines, helping patients to maximize the benefit of their treatments. We are committed to partnering with innovators in the pharmaceutical industry. Visit www.AdarePharma.com and experience a partnership that's truly transformative.62 articles about Adare Pharmaceuticals
-
PharmaTelevision Interview to Spotlight Aptalis Pharmaceutical Technologies President John Fraher
8/22/2011
-
Aptalis Pharmaceutical Technologies Announces FDA Approval of 25,000 Lipase-Unit Strength of ZENPEP(R)
7/15/2011
-
Eurand Pharmaceutical Technologies Release: Webinar: Competitive Advantages of Intelligent Formulation Design
5/25/2011
-
The Newly Combined Axcan and Eurand Pharmaceutical Technologies Announce Name Change to Aptalis
5/5/2011
-
Eurand Pharmaceutical Technologies Reports Recent Highlights and Second Quarter 2010 Financial Results
8/6/2010
-
Eurand Pharmaceutical Technologies Issued U.S. Patent for ZENPEP(R) (pancrelipase) Delayed-Release Capsules
2/16/2010
-
Eurand Announces First Quarter 2008 Financial Results Conference Call
4/17/2008
-
Eurand in Licenses Corticosteroid GI Product From Chiesi Farmaceutici SpA
4/15/2008
-
Eurand (Vandalia, Ohio) Receives a Notice of Allowance for U.S. Patent Application Covering Amrix
4/10/2008
-
Eurand to Present At the Lehman Brothers 11th Annual Global Healthcare Conference
3/10/2008
-
Eurand (Milan, Italy) CEO Gearoid Faherty Recognized by the Boomer Esiason Foundation
3/3/2008
-
Eurand (Milan, Italy) Announces Positive Pharmacokinetic Study Results of Once-a-Day Ondansetron
2/26/2008
-
Eurand (Milan, Italy) Presents at the 10th International Symposium on Antiangiogenic Agents
2/7/2008
-
Eurand (Milan, Italy) Announces Fourth Quarter 2007 and Year-end Financial Results Conference Call
2/4/2008
-
Eurand Appoints Two New Members to Its Board of Directors
9/13/2007
-
Eurand Announces Shareholder Meeting to Appoint New Directors
8/7/2007
-
Eurand (Milan, Italy) Reports First Half 2007 Key Achievements and Financial Results
8/3/2007
-
Eurand (Milan, Italy) Announces Positive Phase III Clinical Study Results
4/4/2007
-
Par Pharmaceutical Companies, Inc. Begins Shipment Of Generic K-Dur(R)
12/6/2004
-
Eurand Receives Approval To Market Generic Potassium Chloride
8/23/2004